CHMP approves MRK’s Keytruda in first-line NSCLC with high PD-L1 expression: http://finance.yahoo.com/news/european-medicines-agency-chmp-recommends-122600542.html The FDA approved Keytruda in this indication in Oct 2016 (#msg-126020834).